SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following the release of positive Week 52 Phase 3 trial results, which investors are positioning as a strong best-in-class indicator for their skin drug, sonelokimab. The community is actively debating the potential for an upcoming acquisition and monitoring institutional accumulation, while some retail traders express frustration over recent price volatility and the timeline for further clinical data readouts.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending as investors bet on the company's pivot from crypto mining to high-demand AI and HPC data center infrastructure, fueled by recent FERC grid connectivity mandates and anticipation of upcoming lease contracts. The community is actively discussing the stock's upward momentum, potential Russell 3000 index inclusion, and the impact of institutional positioning on future price action.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community interest as high trading volume and recent insider activity fuel speculation about potential acquisition interest or upcoming strategic catalysts. Investors are actively discussing the impact of new management's positioning, while closely watching key technical levels and patent developments that could signal a breakout for the stock.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive topline Phase 3 data for its depression treatment, triggering significant investor interest and ongoing debate regarding its potential for commercial success against established psychedelic peers. Community discussions center on the company's clinical trial catalysts, cash runway, and the binary nature of upcoming data readouts in the competitive mental health space.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as investors aggressively bid up memory stocks, fueled by reports of structural storage shortages and AI-driven data center demand. The community is actively debating the sustainability of this parabolic run, with some traders highlighting the stock's record-setting RSI as a sign of an overheating market while others point to institutional re-rating as evidence of a sustained supercycle.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as the market reacts to its latest acquisition of Cyberhawk, a critical infrastructure intelligence firm, alongside anticipation surrounding its upcoming inclusion in the Russell 2000 index. While the community is actively debating the company's aggressive acquisition-based growth strategy and the potential impact of its unified autonomous defense architecture, investors are closely monitoring the stock's consolidation patterns while waiting for further contract-based catalysts.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant selling pressure and heightened volatility, as investors weigh concerns over subscriber growth against management's capital allocation and potential M&A activity. The community remains deeply polarized, with bears aggressively betting on further downside following recent technical breaks, while bulls are scouting for value in what they consider an oversold market leader.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF (DRAM) is trending as investors capitalize on the structural AI-driven demand for HBM and storage, despite broader market volatility and uncertainty surrounding major upcoming IPOs. Community sentiment remains overwhelmingly bullish, with many participants framing the current price action as a strategic entry point for a long-term re-rating of the memory sector beyond its traditional cyclical history.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is under intense focus as China implements new export controls and security reviews on critical minerals, prompting community debate over domestic supply chain independence and the effectiveness of existing government partnerships. Investors are closely monitoring how the company handles compliance and competitive pressures while weighing the broader geopolitical implications of restricted dual-use material access for the U.S. defense industrial base.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing significant volatility following a surprise FDA clinical hold on its gene therapy programs, which triggered investor anxiety ahead of a looming PDUFA date for its Hunter syndrome therapy. While the community remains deeply divided between those citing the potential for an approval and those betting on a complete response letter (CRL) due to safety concerns, investors are actively analyzing how this regulatory setback impacts the long-term viability of the company's broader AAV vector pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Harrow (HROW) delivered earnings and revenue surprises of -48.24% and -12.17%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Misses Q1 Earnings and Revenue Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of -5.09% and -1.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of -18.84% and -80.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Harrow (HROW) Projected to Post Quarterly Earnings on Monday

Harrow (NASDAQ:HROW) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have...

Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research

BTIG Research restated a "buy" rating and set a $63.00 price objective on shares of Harrow in a research report on Friday...

LogiCare3PL Selected as Distribution Partner by Harrow

LogiCare3PL Selected as Distribution Partner by Harrow LogiCare3PL Selected as Distribution Partner by Harrow PR Newswire OLIVE BRANCH, Miss., April 14, 2026 OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a...

Jefferson Bridge Capital LLC Buys Shares of 52,798 Harrow, Inc. $HROW

Jefferson Bridge Capital LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The...

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

HROWHarrow Health Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HROW News